PROBIOMED Competitors and Similar CompaniesClear all

PROBIOMED's competitors and similar companies include Ali Raif and Seriki, AUSTAR Group, Daewoong Pharmaceutical and Shield Healthcare.

	PROBIOMED PROBIOMED is a biopharmaceutical company.	Ali Raif and Seriki Ali Raif and Seriki (ARIS) is a manufacturer of pharmaceutical products.	AUSTAR Group AUSTAR Group (also known AUSTAR Lifesciences) is a technology-based pharmaceutical engineering solution provider.	Daewoong Pharmaceutical Daewoong Pharmaceutical is a healthcare company that provides pharmaceutical solutions and services.	Shield Healthcare Shield Healthcare is a manufacturer and developer of pharmaceutical and medical products and devices.
Founding Date	Founding Date 1970	Founding Date 1963	Founding Date 1991	Founding Date 1945	Founding Date 1957
Type	Type Subsidiary	Type Private	Type Public	Type Public	Type Private
Tags	Tags Healthcare medical devices pharma	Tags Healthcare medical devices pharma	Tags Healthcare medical devices pharma	Tags Healthcare medical devices pharma	Tags Healthcare medical devices pharma
Locations	Locations Ciudad de México, MX HQ Ciudad De México, MX Ciudad De México, MX Tenancingo De Degollado, MX	Locations Istanbul, TR HQ Adana, TR Ankara, TR Antalya, TR Bursa, TR Di̇yarbakir, TR İstanbul, TR see more	Locations CN HQ	Locations Seoul, KR HQ Beijing, CN Benxi, CN Hyderabad, IN Jakarta, ID Pandaan, ID Osaka, JP see more	Locations US HQ
Employees	Employees 637	Employees 682	Employees 1,610	Employees 1,7155% increase	Employees 433
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥1.8b (FY, 2023)	Revenue (est.) ₩1.8t (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥1.5b (FY, 2023)	Cost of goods ₩836.4b (FY, 2023)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ¥343.7m (FY, 2023)	Gross profit ₩981b (FY, 2023)	Gross profit N/A
Net income	Net income N/A	Net income N/A	Net income (¥107.5m) (FY, 2023)	Net income ₩191.4b (FY, 2023)	Net income N/A